MedTrace Logo

Rituximab in Pretreated Elderly or Unfit B-CLL Patients

NCT01576588 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-12-27

Study results available
· View outcomes & findings →

Summary

The study will test the efficacy rituximab in addition to glucocorticoids for the treatment of B-CLL in elderly or unfit patients.

Conditions

  • B-Cell Chronic Lymphocytic Leukemia

Interventions

DRUG

Rituximab

Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).

DRUG

Glucocorticoid

Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.

Sponsors & Collaborators

  • Prof. Dr. Med. Laimonas Griskevicius

    lead OTHER

Principal Investigators

  • Laimonas Griskevicius, MD · Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2016-01-31
Completion
2019-06-30

Countries

  • Lithuania

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01576588 on ClinicalTrials.gov